Dr. Muhunthan Thillai is the Co-founder and CEO of Qureight, a medical technology company in Cambridge which aims to pioneer data curation through advanced AI in complex diseases. By structuring image and biomarker data from biopharma and healthcare institutions, Qureight uses their AI-assisted platform to look for new trial endpoints in complex diseases including Idiopathic Pulmonary Fibrosis, Lung Cancer and Pulmonary Hypertension. Its clients using the platform include the pharmaceutical giants Roche, Galapagos and Takeda. Qureight raised £1.5M seed funding recently led by Playfair Capital in London. Dr. Thillai is also a consultant chest physician at Royal Papworth and Addenbrooke's hospitals and also holds a PhD in Immunology from Imperial College London. His research interests are in lung fibrosis and he is editor of the 2019 Handbook in Interstitial Lung Diseases and co-chair of the 2020 British Thoracic Society guidelines in sarcoidosis. He co-founded and built Qureight which now employs 12 people all during the covid pandemic where he was a busy hospital lung doctor seeing very ill patients and vaccinating the public in his spare time.